By Dr. Ilya Rabkin, MD MBA ·
“Peptide” is a broad category. Some peptides are established medicines; others being sold for recovery or longevity have very little human research behind them.
BPC-157 has interesting animal data around healing, but human evidence remains limited, especially for the under-the-skin injections commonly used today.
FDA’s 2026 reviews found no published clinical studies in which TB-500 or MOTS-c themselves had been administered to humans.
Growth hormone–releasing peptides can raise GH and IGF-1, but that does not necessarily translate into more muscle, better recovery, improved sleep, or healthier aging.
Tesamorelin provides a useful comparison: randomized human trials, an FDA-approved indication, established dosing, and known risks.
I hear some version of this question regularly, often from someone with a nagging tendon or joint problem who has heard that peptides can speed healing.
Sometimes the question is about BPC-157. Sometimes it is CJC-1295, ipamorelin, MOTS-c, or another compound that recently appeared on a podcast or social media.
The problem with the phrase “peptide therapy” is that it covers an enormous range of treatments.
Insulin is a peptide hormone. Oxytocin is a peptide. Semaglutide is a modified peptide. Tesamorelin is a peptide drug.
BPC-157 is also a peptide.
The evidence behind those compounds is dramatically different.
A peptide is a shape, not a promise.
Peptides are short chains of amino acids that often act as biological signals. That makes them excellent potential drugs. A 2025 review estimated that peptide therapeutics accounted for about 8% of FDA drug approvals over the previous decade.1
There is plenty of legitimate reason to be excited about peptide medicine. The challenge is separating that progress from compounds whose popularity has moved much faster than the clinical research.
Rather than trying to memorize which peptide is currently considered promising, I find four questions more useful:
Has it actually been studied in people?
Was it studied for the problem we are trying to treat?
Was it given in roughly the same way people are using it now?
Do we have confidence in what is actually in the product?
Those questions provide a useful framework for looking at some of the peptides people are asking about most often.
Several experimental peptides received a lot of attention in July 2026 when FDA’s Pharmacy Compounding Advisory Committee reviewed them for possible inclusion on the list of substances that certain pharmacies may use in compounding.
BPC-157 and TB-500 each received an 8–6 vote in favor, with one abstention. MOTS-c passed 7–5 with two abstentions.3
FDA’s scientific reviewers had recommended against adding these compounds based on the available evidence.5,6,13
The committee ultimately reached a different conclusion, with some members arguing that access through regulated pharmacies could be preferable to the gray market where these products are already being used.
The vote was not FDA drug approval.
It did not establish that BPC-157, TB-500, or MOTS-c are safe or effective treatments. The committee’s recommendation is advisory, and FDA makes the final regulatory determination.2,3
That distinction became blurred in some of the coverage that followed the meeting.
BPC-157 is probably the best example of both the promise and uncertainty surrounding experimental peptides.
It is commonly promoted for tendon and ligament injuries, joint pain, muscle recovery, wound healing, gut problems, and inflammation.
The animal research is legitimately interesting. Studies have reported effects involving tissue repair, blood-vessel formation, inflammatory pathways, and other parts of the healing process.
A 2025 systematic review focused on orthopedic and sports-medicine applications found 36 relevant studies. Thirty-five were preclinical. Only one involved people, a small retrospective study of patients receiving BPC-157 injections into the knee for chronic knee pain.4
That is enough to make BPC-157 a reasonable research target. It is much less evidence than someone might assume from the confidence with which it is often marketed.
FDA conducted a detailed review in 2026 and identified five small human studies involving BPC-157. They used several different routes, including rectal administration, injection into the knee, administration into the bladder, and a very small intravenous study.5
FDA found no human data showing how the body absorbs and clears BPC-157 after oral, nasal, transdermal, or subcutaneous use.5
That last route matters because injecting BPC-157 under the skin is one of the most common ways it is currently used for injury recovery.
BPC-157 was also nominated for tendinitis, but FDA did not evaluate that use, noting that it could not identify clinical studies in that population.5
So the version of BPC-157 most people hear about—an injection to accelerate tendon, ligament, or muscle healing—still lacks the kind of human trial that would answer the question.
I would very much like to see that trial done. The animal data are interesting enough to justify finding out.
For now, “this could work” and “we know this works” remain different statements.
The human studies so far have been small and short. They did not reveal a clear serious safety signal, but the amount of safety information collected was limited.5
There are no studies specifically looking at cancer risk, and some short-term animal studies raised questions involving clotting tests and liver-related laboratory values.5 Animal findings do not automatically translate to people, but they reinforce how incomplete the long-term safety picture remains.
Claims that BPC-157 has “no side effects” therefore go beyond what we actually know.
TB-500 is often paired with BPC-157 in recovery protocols.
The interest comes from its relationship to thymosin beta-4 biology, which has been studied in cell migration, blood-vessel formation, and wound healing.
Research on TB-500 itself is much thinner.
In its May 2026 review, FDA reported finding no clinical studies in which TB-500 itself had been administered to humans and no human studies establishing its effectiveness or safety.6
That does not prove TB-500 is ineffective. It tells us how early the evidence still is.
CJC-1295, ipamorelin, and sermorelin are different because their basic biological activity is better established.
CJC-1295 stimulates the growth hormone pathway. In two randomized, placebo-controlled studies involving healthy adults, it produced sustained increases in growth hormone and IGF-1.7
Ipamorelin has also been studied in healthy volunteers and produces a measurable release of growth hormone.8
So these compounds can move the hormone numbers.
The more useful question is what happens to the person.
Do they gain meaningful muscle or strength? Recover faster? Sleep better? Lose a meaningful amount of fat? And what are the tradeoffs if GH and IGF-1 remain elevated over long periods?
We have much less evidence for many of those claims.
Stimulating this pathway also carries potential risks. The FDA-approved tesamorelin label warns about elevated blood sugar, fluid retention, joint symptoms, and sustained increases in IGF-1. Active cancer is a contraindication, and a previous history of cancer requires careful consideration.9
Those warnings apply specifically to tesamorelin, but they illustrate why raising GH and IGF-1 should not automatically be treated as a beneficial goal.
Sermorelin has a longer medical history than many of the newer peptides now being marketed for wellness.
Geref, a sermorelin acetate product, was previously FDA-approved for pediatric growth hormone–related uses. It was later discontinued, and FDA subsequently determined that its withdrawal was not because of safety or effectiveness concerns.10
Today, sermorelin is often discussed for adult goals such as sleep, recovery, body composition, and “anti-aging.”
Its earlier medical use tells us that sermorelin is a biologically active compound with human data. It does not establish those broader adult benefits.
Tesamorelin is a useful comparison because it acts on the same general growth hormone pathway but has gone much further through clinical development.
A randomized trial published in the New England Journal of Medicine studied 412 adults with HIV and excess abdominal fat.
After 26 weeks, visceral abdominal fat decreased by 15.2% in the tesamorelin group. It increased by 5.0% in the placebo group. Triglycerides and several other metabolic measures also improved.11
Tesamorelin later received FDA approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Its indication is specific. The current prescribing information states that it is not a general weight-loss medication, and long-term cardiovascular safety has not been established.9
That specificity is useful.
We know who was studied, what dose was used, what outcomes improved, what risks need to be monitored, and what the drug has not been proven to do.
Tesamorelin shows what promising peptide biology looks like after it has been tested much more rigorously in people.
MOTS-c has attracted attention in longevity circles because its biology is unusual.
It is a small peptide encoded within mitochondrial DNA. Mitochondria are best known for producing energy inside cells, but they also help regulate metabolism and how cells respond to stress.
A 2015 study in Cell Metabolism found that MOTS-c influenced pathways the body uses to manage energy and blood sugar and improved insulin sensitivity in mice.12
That opened interesting questions about metabolic health, exercise, mitochondrial function, and aging.
FDA’s 2026 review found no clinical studies in which MOTS-c itself had been administered to humans.13
One finding makes the story even more interesting: in laboratory testing, MOTS-c broke down quickly in human blood. That raises a basic unanswered question. If MOTS-c is injected, does enough intact peptide survive to produce the effects being attributed to it?13
We do not know yet.
That is why I find MOTS-c scientifically interesting. There is real biology here, but its reputation as a human longevity treatment is several steps ahead of the evidence.
Even if an experimental peptide eventually proves effective, product quality still matters.
Compounded medications can serve legitimate medical needs, but compounded drugs are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality as approved medications.14
A product obtained through a legitimate medical and pharmacy pathway is also very different from an online vial labeled “research use only” or “not for human consumption.”
For something being injected, identity, dose accuracy, purity, sterility, and storage all matter.
I am interested in where peptide medicine goes from here.
Some of these compounds may eventually prove far more useful than the evidence allows us to say today. A lack of enormous randomized trials does not automatically make an idea worthless. Trials are expensive, patent economics matter, and promising treatments often spend years in the space between interesting science and established medicine.
But patients should be able to see that uncertainty clearly.
For a specific peptide, I want to know what we are trying to accomplish, whether that outcome has actually been studied in people, how closely the research resembles the proposed use, what we know about safety, and whether a better-studied option already exists.
BPC-157 for a chronic tendon injury, tesamorelin for an established medical indication, and MOTS-c for longevity in an otherwise healthy person should not be treated as variations of the same therapy.
Some of today’s experimental peptides may become important treatments. Until then, patients deserve a clear distinction between an interesting mechanism, promising early research, and a therapy that has actually demonstrated meaningful benefits in people.
Gare CL, White AM, Malins LR. From lead to market: chemical approaches to transform peptides into therapeutics. Trends Biochem Sci. 2025;50(6):467-480. doi:10.1016/j.tibs.2025.01.009.
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Accessed September 21, 2026. fda.gov
Roy S, Niasse A, Sneha SK. FDA advisers back first four of seven unapproved peptides under review for looser rules. Reuters. July 23, 2026. Updated July 24, 2026. Accessed September 21, 2026. reuters.com
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551.
US Food and Drug Administration. Evaluation of BPC-157-related bulk drug substances (BPC-157 [free base] and BPC-157 acetate) for inclusion on the 503A Bulk Drug Substances List. Memorandum dated May 11, 2026. In: FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov
US Food and Drug Administration. Evaluation of TB-500-related bulk drug substances for inclusion on the 503A Bulk Drug Substances List. Memorandum dated May 15, 2026. In: FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/A:1018955126402.
EGRIFTA WR (tesamorelin) for injection [prescribing information]. Theratechnologies Inc; revised March 2025.
US Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Fed Regist. 2013;78(42):14095-14096. March 4, 2013. Docket No. FDA-2012-P-1071.
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375.
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009.
US Food and Drug Administration. Evaluation of MOTS-c-related bulk drug substances (MOTS-c [free base] and MOTS-c acetate) for inclusion on the 503A Bulk Drug Substances List. Memorandum dated May 11, 2026. In: FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov
US Food and Drug Administration. Compounding and the FDA: questions and answers. Accessed September 21, 2026. fda.gov
This article is for educational purposes and does not provide individualized medical advice, diagnosis, or treatment. Peptide therapies differ substantially in their evidence, regulatory status, formulation, and potential risks. Treatment decisions should consider the specific compound, intended use, available human evidence, source of the medication, and the individual patient’s medical history.
ZinovyMed provides personalized, physician-led care focused on prevention, longevity, and your long-term health.
Schedule a Consultation